Posted by MD Biosciences on Tue, Oct 06, 2009 @ 10:45 AM
MD Biosciences (MDB) launches MD Bioproducts, a division of MD Biosciences, in a continued effort to meet client needs for high quality research products. The new division allows MD Biosciences to strengthen and expand it's product offering for immunology and cell biology research while maintaining its contract research focus within inflammation and neurology disease research.
While MD Biosciences has offered its products for purchase since 1991, the new division permits for increased product distribution by 140 percent. Cell Culture Related Reagents, Assays, Antibodies, Proteins, and Western Blot kits are some of the products MD Bioproducts currently provides. Currently, new products and product technologies are being explored and will be added to the development and manufacturing for the coming year.
"At MD Biosciences, our top priority has always been meeting the needs of our clients through the products we offer and customer experience we deliver. The launch of MD Bioproducts is a great step of convenience for our clients-accommodating them to optimize their research process. We know that our products offer accuracy and reproducibility so our clients can be confident in their results. Our quality reagents contribute to the success of our clients' research," stated MD Biosciences President, Eddie Moradian.
Apart from the key benefit of increased manufacturing opportunities, the new division provides a better resource for product purchasers. VP of Marketing & Sales, Amy Clausen said, "MD Bioproducts showcases a new, clean look--including packaging, logo and its own website, which allows for easy navigation and viewing of product features. We are thrilled to be taking this direction at MDB as it will simplify and improve the customer experience for the client." MD Bioproducts website may be visited at
www.mdbioproducts.com.
About MD BiosciencesMD Biosciences provides contract research services including efficacy testing, mode of action platforms, in vitro analysis, and histology for the Pharmaceutical, Medical Device and Animal Health & Nutrition Industries. We offer several novel models in the area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD, pain, and Parkinson's disease. The in-depth expertise in these disease models has been applied to designing protocols to assess the efficacy and required dosage of novel compounds. Contracted studies are designed and reviewed by MDB’s panel of internationally recognized experts and performed at one of MDB’s specialized laboratories located in St. Paul, MN (USA), Glasgow (Scotland) or in Israel. We provide a ready team of experts to tackle problems and provide solutions.
About MD BioproductsMD Bioproducts is a division of MD Biosciences offering high-quality reagents for immunology and cell biology research. Our goal is to provide products that are easy-to-use, accurate and reproducible – ultimately contributing to our client's research success.
###
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Mon, Oct 05, 2009 @ 10:51 AM
MD Biosciences (MDB), a contract research organization offering
pre-clinical services and products in support of drug discovery for
inflammatory and neurological diseases, relocated its U.S. office from
1000 Westgate Dr, St Paul, MN to 2575 University Ave W, St Paul, MN on
October 3, 2009. The new location equips MD Biosciences with more lab
space, allowing for increased capacity for in vitro services and
product development and manufacturing to increase product offering.
Eddie
Moradian, President of MD Biosciences states, "At MD Biosciences, we
have always promised our clients that we will meet their needs now and
in the future; our expansion ensures that commitment. We doubled our
lab space so that we are able to provide 150 percent more services and
increase product development by 130 percent in the coming year in
comparison with the last.
Our relocation is just one step of
many in the endeavor to continue to offer the highest quality services
and products in assisting our customers in meeting their objectives.
Future projections include adding more highly specialized scientists to
our team and increasing our focus on our available products and
proprietary reagents."
About MD BiosciencesMD
Biosciences provides products and pre-clinical services, which include
efficacy testing, mode of action platforms, in vitro analysis,
histology and imaging for the Pharmaceutical, Medical Device and Animal
Health & Nutrition Industries. We offer several novel models in the
area of rheumatoid arthritis (RA), Multiple sclerosis, asthma, IBD,
pain, and Parkinson's disease. The in-depth expertise in these disease
models has been applied to designing protocols to assess the efficacy
and required dosage of novel compounds. Contracted studies are designed
and reviewed by MDB’s panel of internationally recognized experts and
performed at one of MDB’s specialized laboratories located in St. Paul,
MN (USA), Glasgow (Scotland) or in Israel . We provide a ready team of
experts to tackle problems and provide solutions. MDB also supplies for
purchase by all laboratories many of the products and proprietary
reagents used in our research, regardless of whether MDB is contracted
as a research organization. This allows our clients to optimize their
own research process by selecting steps to be performed by MDB and
research to be performed in-house.
###
The
information in this press release should be considered accurate only as
of the date of the release. MD Biosciences has no intention of updating
and specifically disclaims any duty to update the information in these
press releases.
Posted by Amy Clausen on Wed, Mar 04, 2009 @ 11:03 AM
Wednesday, March 4, 2009, St. Paul, MN - MD Biosciences, a Preclinical Contract Research Organization (CRO), announces today that it has expanded its preclinical contract research services by launching a line of in vivo models for the study o fmyocardial infarct and vascular disease. These models enable the evaluation of drug treatment for myocardial infarct.
New models include:
- Ligation induced acute cardiac infarction
- Coil-induced acute cardiac infarction
- Balloon-induced cardiac ischemia reperfusion
- Multi-focal myocardial infarct
- Induction of vascular disease
These models offer the flexibility of protocol design for monitoring a variety of parameters such as ECG, invasive blood pressure, SpO2, ETCO2, and PPV. Readouts offered include ECG, Echo, Angiography, cardiac MRI and blood tests for relevant parameters such as CPK. All tests are analyzed by expert cardiologists in collaboration with the Heart Institute, Sheba Medical Center of the Tel Aviv University.
The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.
eba Medical Center of the Tel Aviv University.
The expansion of these service capabilities, along with the addition of scientific staff, indicates the stability and forward growth of the company. MD Biosciences complete services portfolio offers efficacy testing, mode of action analysis, biomarker and gene expression analysis and histopathology services. In vivo models include Collagen Induced Arthritis (CIA), Antibody Induced Arthritis, OVA-induced Asthma, DSS and TNBS induced IBD, EAE/Multiple Sclerosis, Neuropathic Pain, Nociceptive Pain, Post-operative Pain and Parkinson’s Disease. In vitro cell based services include assays for screening of inflammatory effects, cell signaling pathway screens, enzyme inhibition assays as well as molecular mode of action assays.
About MD Biosciences
MD Biosciences is a Preclinical Contract Research Organization (CRO) providing services and products for biotech/pharmaceutical, medical device and animal health and companies engaged in inflammations & neurology research. With specialized laboratories located in Minnesota, Glasgow, and Israel, our panel of internationally recognized experts provides in-depth expertise and technologies to overcome challenges and provide total solutions to the drug discovery market.
--------
The information in this press release should be considered accurate only as of the date of the release. MDB has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Tue, Nov 11, 2008 @ 11:15 AM
St Paul, MN, November 11, 2008 – MD Biosciences, a global biotechnology company focused in inflammations & neurology research will showcase its pre-clinical capabilities at the 2008 Neuroscience Conference in Washington, DC, November 15 – 19th, 2008, booth 1825. Capabilities included in the showcase are efficacy disease models within Multiple Sclerosis (MS), Gliosis, Parkinson’s Disease, Nociceptive, Neuropathic, Post-operative
and Inflammatory Pain.
Multiple Sclerosis:
Multiple sclerosis is a demyelinating disease of the CNS. Due to the clinical and pathological similarities of EAE and MS, EAE has been used as a model for the study of human demyelinating disease and is characterized by a relapsing-remitting disease course with subsequent progressive disability.
- MBP-induced EAE
- MOG-induced EAE
- PLP-induced EAE.
Gliosis:
Gliosis is a proliferation of astrocytes in the central nervous system (CNS) in response to injury which results in scar formation. Astrocytes react to injury by hypertrophy and up-regulation of the glial-fibrillary acidic protein. Gliosis, along with neuronal loss, is
a prominent feature of many diseases of the central nervous system.
Parkinson’s Disease:
Parkinon's Disease (PD) is a neurogenerative disorder characterized by reduction in striatial (DA) content caused by the loss of dopaminergenic neurons in the Substantia Nigra part compacta (SNpc) and their proportions to the striatum.
- Acute MPTP
- Chronic MPTP
- 6-OHDA
Pain:
MD Biosciences offers Nociceptive, Neuropathic and Inflammatory Pain models:.
- Tail Flick
- Visceral Pain
- Caspaicin
- Post-operative pain
- Chronic Constriction Injury (CCI, Bennett & Xie)
- Taxol induced Neuropathic Pain
- Spinal Nerve Ligation (Chung)
- STZ Diabetic Neuropathy
- Carrageenan Induced Inflammatory Pain
- Adjuvant (CFA) induced Inflammatory Pain
- Arthritic and Monoarthritic Pain.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of
scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Wed, Sep 10, 2008 @ 11:23 AM
MD Biosciences, a global biotechnology company focused in inflammations and neurology research, is expanding its line of arthritis and pain preclinical services with the addition of the CFA-induced monoarthritic pain model. The model offers advantages over traditional arthritis models in that disease develops in only one joint allowing a comparison to the healthy joint. The quantification of pain associated with arthritis can be useful in elucidating the mechanisms of arthritis as well as evaluating the efficacy of anti-arthritic drug compounds in the discovery phase.
The monoarthritic pain model is a 28-day model with arthritis and subsequent pain present in a single joint. Pain response develops 1 day post-induction. Readouts available are clinical signs and scoring, body weights, mechanical and thermal stimuli, weight bearing, histology and cytokine analysis.
In addition to the monoarthritic pain model, MD Biosciences offers the traditional Adjuvant-induced arthritis model that allows for traditional pain measurements as well as a record of spontaneous pain using the Foot Print of Pain method. Other Arthritis models and research reagents include the Collagen Induced Arthritis (CIA) and Collagen Antibody Induced Arthritis (CAIA), ArthritoMab™ Arthritogenic Antibody Cocktail, Collagen Reagents, Collagen Antibodies and Collagen-related ELISA Kits and Assays.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland and has specialized laboratories located in the United States, United Kingdom, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Mon, Mar 03, 2008 @ 11:27 AM
St Paul, MN March 4, 2008 – MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new line of Mouse anti-Collagen Type II (anti-mouse CII) ELISAs. The new Mouse anti-collagen CII ELISAs allow you to measure antibodies generated against the species of collagen used in the induction of arthritis in mice (bovine, human, mouse, rat, chicken, porcine). IgG and two subclasses (IgG2a and IgG2b) are now available as ready-to-use ELISAs that provide fast, accurate and reliable results.
The Collagen-induced arthritis (CIA) model is one of the most widely used models for the study of RA. Collagen type II (CII) in adjuvant is used to induce arthritis by triggering autoreactive B cells, which play an important role in the development of arthritis. This B cell response to CII is strictly T cell dependent, where the B cells predominantly switch isotype to IgG.
The anti-Type II Collagen ELISAs offer many improvements over other commercially available anti-Collagen Type II ELISAs. The kits come ready to use eliminating any plate coating or blocking as well as eliminates lengthy sample incubations. The assays can be completed in under 3 hours using only 100 uL of sample. Performance characteristics such as precision CVs less than 10%, recovery and linearity averaging at 82% and 102% respectively, and cross-reactivity with other collagen types of less than 0.004% provide reliable, accurate and sensitive assays for the detection mouse Collagen Type II antibodies.
The addition of these assays enhances the arthritis products and services currently offered by MD Biosciences. Research products include assays for measuring type II collagen and antibodies, assay for staining type II collagen, induction reagents such as collagen, adjuvant and ArthritoMabÒ antibody cocktail. Pre-clinical services include collagen-induced arthritis (CIA), Antibody induced arthritis (CAIA), Adjuvant Induced Arthritis as well as in vitro disease models providing the researcher a well-rounded approach for using MD Biosciences products in-house as well as outsourcing other areas of their drug discovery platform.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Fri, Aug 03, 2007 @ 11:30 AM
MD Biosciences, a global biotechnology company focused in inflammations research, announces the recent launch of its new Mouse OVA-IgE ELISA. The OVA-IgE ELISA offers researchers sensitive, reproducible, accurate and reliable results for the measurement of OVA specific IgE in mouse serum and cell culture supernate samples. The kit is ready-to-use with all necessary reagents and can be completed in under 2.5 hours, requires small sample sizes and measures levels down to 7.8 ng/mL with a sensitivity of less than 3.8 ng/mL.
Ovalbumin is widely used in inducing an allergic response in mouse models of allergic asthma. Through T cell and B cell signalling, IgE production is stimulated and released into the bloodstream where IgE attaches to cells such as mast cells and basophils. These cells are then activated after the IgE is cross-linked with antigen, initiating the allergic cascade.
In addition the Mouse OVA-IgE ELISA, MD Biosciences also offers other reagents such as T1/ST2 antibodies, in vitro assay services and efficacy disease models for the study of allergic asthma.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Tue, Apr 03, 2007 @ 11:33 AM
MD Biosciences releases histology
results from an 18-day model of arthritis induced using the
ArthritoMab(TM) cocktail of arthritogenic antibodies in Balb/c mice.
Results show significant histological changes in the joint of the
arthritis group as compared to the normal control group after just 18
days, providing researchers valuable data quickly compared to the
traditional collagen-induced arthritis (CIA) model, which can take
several weeks or more to produce similar histological results.
Results show significant histological changes in the joint of the arthritis group as compared to the normal control group after just 18 days, providing researchers valuable data quickly compared to the traditional collagen-induced arthritis (CIA) model, which can take several weeks or more to produce similar histological results. Figures 1-3 show the effectiveness of the arthritogenic antibodies, with mean histology scores and staining sections indicating the degree of erosion, hyperplasia and infiltration in the joint of the arthritis group as compared to the control group.
The ArthritoMabTM Arthritogenic Antibody Cocktail is comprised of 4 monoclonal antibodies to collagen type II (CII) that have been chosen for their epitope specificity. An antibody response to certain epitopes is better associated with arthritis than a response to other epitopes. In the CIA model, the antibody response correlated with arthritis was mainly
associated with binding to the epitopes C1, J1, and U1. The ArthritoMabTM monoclonal antibodies were selected to bind to the epitopes C1, J1, U1 and D3 - which are spread over the entire CII region (fragments CB8, CB10 and CB11) encouraging better immune complex formation on the cartilage surface for the initiation of arthritis. The antibody-induced arthritis model using the ArthritoMabTM Arthritogenic Antibody cocktail is a rapid alternative the CIA model.
About MD Biosciences
MD Biosciences provides products and pre-clinical services for companies engaged in inflammations and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies’ in-depth expertise and technologies to tackle problems and provide flexible drug discovery solutions, enabling smarter results faster.
###
The information in this press release should be considered accurate only as of the date of the release. MD Biosciences has no intention of updating and specifically disclaims any duty to update the information in these press releases.
Posted by Amy Clausen on Wed, Feb 28, 2007 @ 11:36 AM
St Paul, MN, January 9, 2007 - MD Biosciences, a global biotechnology company focused in inflammations research, accounces the launch of its new and improved Collagen Type II (CII) ELISA for the study of collagen metabolism. CII is a triple stranded pro-molecule that is found predomiinantly, but not exclusively, in cartilage. It's promary role is to provide cartilage with tensile strength and elasticity. Autoimmunity to CII is thought to play a role in the pathogenesis of many autoimmune diseases such as rheumatoid arthritis.
This ELISA offers many improvements over other commercially available CII ELISAs such as increased sensitivity, reproducibility, and accuracy for the reliability of results. The ELISA is designed to quantify the amount of collagen type II produced by cells or present in tissue across a variety of species. The ELISA is also highly specific to CII offering no cross-reactivity to other types of collagen providing reliable results.
In addition to performance improvements, user-friendly improvements such as pre-coated microplates and ready-to-use reagents increase the usability and decrease the preparation time allowing researchers to obtain rapid results in less than 5 hours.
About MD Biosciences
MD Biosciences provides products and pre-clinical services to companies engaged in inflammation and neurology research. The company is headquartered in Switzerland under Morwell Diagnostics and has specialized laboratories located in Minnesota, Glasgow, and Israel. A panel of scientific experts provides companies' in-depth expertise and technologies to provide flexible drug discovery solutions, enabling smarter results faster.